The title of my column is “Hope Is My Superpower.” In my efforts to bring hope to multiple myeloma patients, I try to focus…
Myeloma
We carry many stories in our hearts. The story of how our own life should play out. The story of a peaceful retirement. The story…
A clinical trial in Australia that’s testing the genetic therapy KLN-1010 in people with hard-to-treat multiple myeloma has won regulatory approval to add new…
Today, Jan. 26, is the first day of tax season here in the U.S. Last week, our accountant emailed her annual reminder to collect the…
The other day, I discovered an old, folded road map in the glove compartment. It had faded colors and deep creases. After I spread it…
Treatment with Tecvayli (teclistamab) was better than standard therapies at delaying disease progression and prolonging survival among previously-treated myeloma patients in a Phase…
Here’s a ray of hope from the American Cancer Society (ACS): Its recently released annual Cancer Statistics report noted that the five-year relative cancer…
Yesterday morning, I burned the toast. It wasn’t just a little, either. It was blackened to a crisp and set off the smoke alarm with…
Johnson & Johnson is now seeking regulatory approval in the European Union for Tecvayli (teclistamab) plus Darzalex Faspro (daratumumab and hyaluronidase-fihj) for…
We’re nearly two weeks into the new year and I’m wondering, how are your resolutions going? If your answer is, “Not so well,” take heart…
Recent Posts
- Partners to collect real-world data to speed care for kids with AML
- Study finds home transfusions safe in hospice care for blood cancer
- Small acts of defiance are the ways we push back against disease
- Under-the-skin myeloma treatment linked to better survival in study
- Add-on therapy shows promise for hard-to-treat AML